Sun Pharma Advanced Research Company Ltd

SPARC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharma Advanced Research Company Ltd

₹ 333 -5.00%
19 Apr - close price
sparc.life BSE: 532872 NSE - BE : SPARC
About

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

Key Points

Leadership[1]
First listed pharma R&D company out of India where founders still own 70% and continue to invest.

Website BSE NSE - BE
  • Market Cap ₹ 10,792 Cr.
  • Current Price ₹ 333
  • High / Low ₹ 474 / 178
  • Stock P/E
  • Book Value ₹ 10.2
  • Dividend Yield 0.00 %
  • ROCE -106 %
  • ROE -144 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 32.5 times its book value
  • Company has low interest coverage ratio.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Miscellaneous

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
22 28 22 28 62 25 28 32 131 48 24 21 14
85 78 76 83 73 92 107 94 115 137 126 113 116
Operating Profit -63 -50 -54 -55 -11 -67 -78 -63 16 -90 -102 -91 -103
OPM % -289% -180% -245% -196% -18% -264% -275% -198% 12% -188% -427% -432% -740%
2 0 0 5 0 0 0 0 0 11 10 8 6
Interest 4 4 5 3 2 2 2 3 3 0 0 0 0
Depreciation 3 3 3 3 3 3 3 3 3 3 3 3 3
Profit before tax -68 -57 -61 -55 -16 -71 -82 -68 10 -82 -95 -86 -100
Tax % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-68 -57 -61 -55 -16 -71 -82 -68 10 -82 -95 -86 -100
EPS in Rs -2.58 -2.16 -2.34 -2.09 -0.60 -2.61 -3.03 -2.52 0.37 -2.53 -2.94 -2.66 -3.07
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
29 87 167 156 161 181 78 183 77 253 137 239 107
99 104 134 191 224 304 321 334 387 388 324 453 493
Operating Profit -70 -17 34 -35 -63 -123 -243 -151 -310 -135 -187 -214 -386
OPM % -241% -19% 20% -23% -39% -68% -310% -83% -404% -53% -136% -90% -362%
1 2 10 3 3 14 54 14 10 5 7 11 36
Interest 0 4 6 0 2 2 0 0 3 11 13 8 1
Depreciation 3 3 4 7 8 8 8 8 9 11 10 12 12
Profit before tax -72 -22 34 -40 -70 -119 -197 -145 -312 -151 -203 -223 -363
Tax % 0% 0% 12% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-72 -22 30 -40 -70 -119 -197 -145 -312 -151 -203 -223 -363
EPS in Rs -2.93 -0.91 1.23 -1.60 -2.83 -4.82 -7.85 -5.55 -11.92 -5.77 -7.48 -6.86 -11.20
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 11%
5 Years: 25%
3 Years: 46%
TTM: -51%
Compounded Profit Growth
10 Years: %
5 Years: 2%
3 Years: 9%
TTM: -72%
Stock Price CAGR
10 Years: 8%
5 Years: 14%
3 Years: 26%
1 Year: 71%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: -144%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 21 24 24 24 24 25 25 26 26 26 27 32 32
Reserves -87 85 116 76 8 133 160 270 -45 -194 -230 480 299
68 81 5 4 56 3 2 2 67 236 79 16 14
84 20 39 39 75 111 122 101 224 162 404 302 322
Total Liabilities 86 209 184 143 163 273 309 398 273 230 280 830 667
64 66 64 67 70 69 52 58 104 91 92 106 132
CWIP 1 0 1 0 1 1 3 24 32 5 26 27 2
Investments 0 97 6 0 0 10 108 211 8 6 12 291 151
21 46 112 76 92 192 146 106 128 127 150 406 382
Total Assets 86 209 184 143 163 273 309 398 273 230 280 830 667

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-69 -95 37 -41 -44 -128 -183 -172 -211 -152 -208 -69
-2 -99 44 53 -13 -7 -105 -102 155 2 -29 -548
72 194 -81 -1 51 194 224 274 55 159 229 617
Net Cash Flow 0 -0 -0 11 -7 60 -63 0 0 9 -8 -1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 54 105 61 47 21 78 82 20 76 25 74 50
Inventory Days 0 0 0 0 0 0 0 0 0 0 0
Days Payable
Cash Conversion Cycle 54 105 61 47 21 78 82 20 76 25 74 50
Working Capital Days -899 72 129 21 -42 -59 -232 -98 -557 -96 -97 -189
ROCE % -1,034% -20% 21% -32% -71% -94% -143% -62% -183% -242% -106%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
68.46% 68.10% 68.10% 69.09% 69.09% 69.09% 68.23% 65.68% 65.68% 65.68% 65.68% 65.68%
2.61% 2.54% 2.51% 2.38% 2.40% 2.38% 3.48% 3.64% 3.64% 3.67% 3.30% 3.24%
0.02% 0.56% 0.55% 0.76% 0.76% 0.76% 0.76% 0.63% 0.63% 0.65% 0.67% 0.67%
28.91% 28.81% 28.84% 27.77% 27.75% 27.77% 27.53% 30.04% 30.06% 29.99% 30.36% 30.41%
No. of Shareholders 1,10,30194,83495,03992,73694,49493,71896,33798,7771,00,8071,01,4331,03,9901,02,743

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls